Text adapted in 2023 from "Opioid Use and Opioid Use Disorders" in The Primary Care Addiction Toolkit. Available online only.
American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA: American Psychiatric Association.
American Society of Addiction Medicine. (n.d.). Definition of addiction.
American Society of Addiction Medicine. (2020). ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update.
Auriacombe, M., Fatséas, M., Dubernet, J., Daulouède, J.P. & Tignol, J. (2004). French field experience with buprenorphine. American Journal of Addiction, 13 (Suppl. 1), S17–S28.
Ballantyne, J.C. (2006). Opioids for chronic nonterminal pain. Southern Medical Journal, 99, 1245–1255.
Becker, W.C., Sullivan, L.E., Tetrault, J.M., Desai, R.A. & Fiellin, D.A. (2008). Non-medical use, abuse and dependence on prescription opioids among U.S. adults: Psychiatric, medical and substance use correlates. Drug and Alcohol Dependence, 94, 38–47.
Borron, S.W., Monier, C., Risède, P. & Baud, F.J. (2002). Flunitrazepam variably alters morphine, buprenorphine, and methadone lethality in the rat. Human & Experimental Toxicology, 21, 599–605.
British Columbia Centre on Substance Use. (2017). A Guideline for the Clinical Management of Opioid Use Disorder.
Bromley, L., Kahan, M., Regenstreif, L., Srivastava, A. & Wyman, J. (2021). Methadone Treatment for People Who Use Fentanyl: Recommendations.
Bruneau, J., Ahamad, K., Goyer, M., Poulin, G., Selby, P., Fischer, B. . . . Wood, E. (2018). Management of opioid use disorders: A national clinical practice guideline. Canadian Medical Association Journal, 190, E247–E257.
Busse, J.W., Craigie, S., Juurlink, D.N., Buckley, D.N., Wang, L., Couban, R.J. . . . Guyatt, G.H. (2017). Guideline for opioid therapy and chronic noncancer pain. Canadian Medical Association Journal, 189, E659–E666.
CA Bridge Program. (2020). Starting Buprenorphine Immediately After Reversal of Opioid Overdose.
Canadian Agency for Drugs and Technologies in Health. (2019). In brief: Buprenorphine for opioid use disorder.
Canadian Pharmacists Association. (2021). Compendium of Pharmaceuticals and Specialties (eCPS).
Canadian Research Initiative in Substance Misuse (CRISM). (2018). CRISM National Guideline for the Clinical Management of Opioid Use Disorder.
Canadian Research Initiative in Substance Misuse (CRISM). (2019). National Clinical Guideline: Injectable Opioid Agonist Treatment: iOAT for Opioid Use Disorder.
Centre for Addiction and Mental Health (CAMH). (2021). Opioid Agonist Therapy: A Synthesis of Canadian Guidelines for Treating Opioid Use Disorder.
Centre for Effective Practice. (2017). Opioid Manager.
Centre for Effective Practice. (2018a). Management of Chronic Non-cancer Pain.
Centre for Effective Practice. (2018b). Urine Drug Screening (UDS).
Centre for Effective Practice. (2018c). Management of Chronic Non-cancer Pain: Appendices.
Centre for Effective Practice. (2018d). Opioid Tapering Template.
Cheattle, M.D., Compton, P., Dhingra, L., Wasser, T.E. & O’Brien, C.P. (2019). Development of the revised Opioid Risk Tool to predict opioid use disorder in patients with chronic non-malignant pain. Journal of Pain, 20, 842–851.
Chelminski, P.R., Ives, T.J., Felix, K.M., Prakken, S.D., Miller, T.M., Perhac, J.S. . . . Pignone, M.P. (2005). A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic noncancer pain and a high burden of psychiatric comorbidity. BMC Health Services Research, 5 (1), 3.
Drug Shortages Canada. (2023). Discontinuation report: Probuphine.
Fairbairn, N., Ross, J., Trew, M., Meador, K., Turnbull, J., MacDonald, S. . . . Sutherland, C. (2019). Injectable opioid agonist treatment for opioid use disorder: A national clinical guideline. Canadian Medical Association Journal, 191, E1049–E1056.
Fishbain, D.A., Cole, B., Lewis, J., Rosomoff, H.L. & Rosomoff, R.S. (2008). What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Medicine, 9, 444–459.
Fleming, M.F., Davis, J. & Passik, S.D. (2008). Reported lifetime aberrant drug-taking behaviors are predictive of current substance use and mental health problems in primary care patients. Pain Medicine, 9, 1098–1106.
Health Canada. (2020). Canadian Alcohol and Drugs Survey (CADS): Summary of Results for 2019.
Health Canada. (2021). Subsection 6(1) class exemption for patients, practitioners and pharmacists prescribing and providing controlled substances in Canada.
Jamison, R.N., Ross, E.L., Michna, E., Chen, L.Q., Holcomb, C. & Wasan, A.D. (2010). Substance misuse treatment for high-risk chronic pain patients on opioid therapy: A randomized trial. Pain, 3, 390–400.
Klimas, J., Gorfinkel, L., Fairbairn, N., Amato, L., Ahamad, K., Nolan, S. . . . Wood, E. (2019). Strategies to identify patient risks of prescription opioid addiction when initiating opioids for pain: A systematic review. JAMA Network Open, 2 (5), e193365.
Lintzeris, N., Dunlop, A.J., Haber, P.S., Lubman, D.I., Graham, R., Hutchinson, S. . . . Tiberg, F. (2021). Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: A randomized clinical trial. JAMA Network Open, 4 (5), e219041.
Manchikanti, L., Cash, K.A., Damron, K.S., Manchukonda, R., Pampati, V. & McManus, C.D. (2006a). Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables. Pain Physician, 9, 215–225.
Manchikanti, L., Manchukonda, R., Damron, K.S., Brandon, D., McManus, C.D. & Cash, K. (2006b). Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician, 9, 57–60.
Maumus, M., Mancini, R., Zumsteg, D.M. & Mandali, D.K. (2020). Aberrant drug-related behavior monitoring. Ochsner Journal, 20, 358–361.
Miller, S.C., Fiellin, D.A., Rosenthal, R.N. & Saitz, R. (Eds.). (2018). ASAM Principles of Addiction Medicine (6th ed.). Rockville, MD: American Society of Addiction Medicine.
Moulin, D.E., Clark, A.J., Gilron, I., Ware, M.A., Watson, C.P.N., Sessle, B.J. . . . Velly, A. (2014). Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Research & Management, 19, 328–335.
Ritvo, A.D., Calcaterra, S.L. & Ritvo, J.I. (2021). Using extended release buprenorphine injection to discontinue sublingual buprenorphine: A case series. Journal of Addiction Medicine, 15, 252–254.
Selby, P., Rieb, L., Lam, V., Zhang, M. & Bertram, J. (2022). Opioid Agonist Therapy: A Prescriber’s Guide to Treatment. Toronto, ON: Centre for Addiction and Mental Health.
Substance Abuse and Mental Health Services Administration (SAMHSA). (2022). 2021 National Survey of Drug Use and Health (NSDUH).
Tan, G., Jensen, M.P., Thornby, J.I. & Shantief, B.F. (2004). Validation of the Brief Pain Inventory for chronic nonmalignant pain. Journal of Pain, 5, 133–137.
Voon, P., Karamouzian, M. & Kerr, T. (2017). Chronic pain and opioid misuse: A review of reviews. Substance Abuse Treatment, Prevention and Policy, 12, 36.
Wiedemer, N.L., Harden, P.S., Arndt, I.O. & Gallagher, R.M. (2007). The opioid renewal clinic: A primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Medicine, 8, 573–584.
Wilsey, B.L., Fishman, S.M., Tsodikov, A., Ogden, C., Symreng, I. & Ernst, A. (2008). Psychological comorbidities predicting prescription opioid abuse among patients in chronic pain presenting to the emergency department. Pain Medicine, 9, 1107–1117.
